# Pre-Transplant INCBB099280 for Hepatocellular Carcinoma (HCC)

> **NCT06337162** · PHASE1 · WITHDRAWN · sponsor: **Abramson Cancer Center at Penn Medicine**

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** INCB099280

## Key facts

- **NCT ID:** NCT06337162
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-05-01
- **Primary completion:** 2027-05-01
- **Final completion:** 2028-09-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Incyte made a strategic business decision to stop enrollment to all ongoing oral PD-L1 (99280) studies. This decision was made based on an internal review and reprioritization of the existing pipeline.
- **Last updated:** 2024-08-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06337162

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06337162, "Pre-Transplant INCBB099280 for Hepatocellular Carcinoma (HCC)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06337162. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*